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CASE REPORTA case of exuberant cutaneous lymphomagenesis in
the setting of chronic patch mycosis fungoides
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MF: mycosis fungoidesINTRODUCTION
Patients with mycosis fungoides (MF) are
at increased risk of a second malignant neoplasm,
especially lymphoma.1 We report a sexagenarian
with a 14-year history of patch MF, stage IB, who
had intravascular cutaneous anaplastic large cell
lymphoma (ALCL) and cutaneous composite
lymphoma (CL) of B-cell and T-cell origin in sequen-
tial series as late complications.CASE REPORT
The clinical presentation of both lymphomas
was similar, consisting of eruptive asymptomatic
papulonodular lesions invariably associated with
preexisting patch MF without adenopathy or other
constitutional symptoms (Fig 1). Biopsy of the first
lesion, which developed over the left suprabrow,
found dilated ectatic vascular structures in the
dermis and subcutis with intraluminal large,
pleomorphic, mononuclear cells positive for
CD3, CD4, bF1, and CD30 (Fig 2). Results of CD20,
CD56, Alk-1, EMA, and Epstein-Barr virus (EBV)
in situ hybridization studies were negative.
Peripheral blood flow cytometry findings were
unremarkable. Results of positron emission
tomography/computed tomography and a bone
marrow biopsy were normal. On the basis
of the exclusive intraluminal location of the
neoplastic cells, the anaplastic cytology, the
CD301/Alk-1enegative phenotype, and a negative
staging workup, a diagnosis of cutaneous
intravascular ALCL was rendered, and the patient
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The patient remained clear except for residual
patch MF until late 2013 when multiple smooth
erythematous papules developed on the torso.
Multiple skin biopsies found a mixed bandlike and
focally nodular dermal mononuclear infiltrate
comprised of immunophenotypically distinct B-cell
and T-cell populations (Figs 3 and 4). In situ
hybridization studies for EBV were negative.
Immunoglobulin heavy chain and T-cell receptor
gene rearrangement studies by polymerase chain
reaction confirmed dual B-cell and T-cell clones.
This T-cell clone was identical to the original T-cell
clone identified a decade prior when the original
diagnosis of MF was made. Repeat positron emis-
sion tomography/computed tomography staging
and peripheral blood flow cytometry findings were
unremarkable. Given the negative staging workup
and the simultaneous presence of 2 morphologically
distinct lymphomas at a single tissue site, a diagnosis
of composite lymphoma comprised of MF and
primary cutaneous B-cell marginal zone lymphoma
was rendered. Systemic treatment was deferred
given a lack of symptoms, limited skin involvement,
and the indolent nature of the B-cell component.Pablo Road, Jacksonville, FL 32224. E-mail: Sluzevich.Jason@
mayo.edu.
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Fig 1. A, New-onset infiltrated arciform thin plaque over
left suprabrow. B, Eruptive smooth papules (black arrows)
admixed with chronic epidermally atrophic annular
patches.
Fig 2. Dilated ectatic blood vessels in the dermis and
subcutis (A) with intravascular pleomorphic anaplastic
cells (B) positive for CD30 (C). (A and B, hematoxylin-
eosin stains; original magnifications: A, 34; B, 340; C,
original magnification: 320).
Fig 3. Shave biopsy from a chronic patch shows a
bandlike and focally nodular atypical mononuclear super-
ficial dermal infiltrate. (Hematoxylin-eosin stain, original
magnification: 310). The bandlike component had posi-
tivity for CD2, CD3 (inset, original magnification: 310),
and CD4. The nodular aggregates were CD20 positive
(inset, original magnification: 310). The identified B-cell
and T-cell populations were clonal by gene rearrangement
studies.
Fig 4. Punch biopsy from a new-onset papule shows
nodular dermal aggregates (hematoxylin-eosin; original
magnification: 310) of B cells positive for CD79a, CD20
(inset, original magnification: 310), and BCL-2 but nega-
tive for CD5, BCL-6, CD10, and CD23 consistent with
cutaneous marginal zone lymphoma. These aggregates
were surrounded by a T-cell infiltrate that on the lateral
edges was bandlike in configuration and positive for CD3
and CD4 (inset, original magnification: 310) and negative
for CD8 and CD30. Dual clonal B-cell and T-cell popula-
tions were identified by gene rearrangement studies.
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Cutaneous intravascular ALCL and cutaneous CL
are very rare entities. Most composite lymphomas
involving the skin have an underlying systemic B-cell
component derived from chronic lymphocytic
leukemia or small lymphocytic lymphoma.2
Uniquely, the B-cell component in this case
is cutaneous in origin with a marginal zone
phenotype given an absence of bcl-6/CD23 staining
and an associated T-cellerich infiltrate.3 Although
cutaneous lymphoid hyperplasia and cutaneous
marginal zone lymphoma may have morphologic
overlap, the presence of clonality along with anabsence of eosinophils, tingible foreign body mac-
rophages, and a mixed T-cell infiltrate is most
consistent with the latter.4 This finding represents a
true cutaneous composite lymphoma and not simply
a secondary B-cell lymphoma, as skin biopsies and
immunohistochemical and molecular analyses
demonstrate the simultaneous coexistence of 2
distinct primary cutaneous B-cell and T-cell
lymphomas. The presence of dual B-cell and T-cell
clones is strong evidence against the possibility of
phenotypic lineage infidelity, whereby a T-cell
lymphoma develops aberrant expression of B-cell
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reflect genotypic lineage infidelity, as there is
morphologic evidence of a cutaneous B-cell
lymphoma and T-cell lymphoma in the setting of
an identical T-cell clone identified a decade prior.
With the exception of this index case, previous
descriptions of intravascular cutaneous ALCL do not
show a consistent association with pre-existing MF
and more prototypically develop de novo as solitary
or progressive papulonodular eruptions.5 Attempts
in this case to clonally link the prior MF with the
subsequent intravascular cutaneous ALCL were not
successful, as there was inadequate amplification of
both T-cell receptor target DNA and an internal
control despite the use of laser microdissection.
The clinical presentation and histopathologic
features were also not consistent with large cell
transformation of MF.6 Other benign intravascular
CD301 proliferations simulating intravascular
lymphoma have a pyogenic granulomalike histo-
pathology and a significant inflammatory cell
component and were absent in this case.7
The optimal treatment of intravascular cutaneous
ALCL is unknown. Systemic chemotherapy was
selected in this case, as most intravascular large
B-cell lymphomas and EBV1 natural killer/T-cell
lymphomas exhibit rapid systemic dissemination.
Our patient has not had a recurrence of ALCL since
the end of systemic chemotherapy 4 years ago.
Similar favorable long-term outcomes have been
observed in other cases, suggesting that skin-limited
intravascular CD301 ALCL may be a distinctive
clinical pathologic entity with potentially indolent
behavior akin to other extravascular cutaneous
CD301 lymphoproliferative disorders.8 In this
context, consideration of skin-directed therapy or
low-dose oral methotrexate as initial therapy is
warranted.
Patients with MF may have multiple other
lymphomas that rarely may be purely cutaneous in
origin. The initial clinical presentation may mimicworsening or transformed MF; thus, early consider-
ation should be given to biopsy of lesions discordant
from prior baseline. Long-term prognosis is related
the specifics of the underlying subsequent
lymphoma, which, in the case of skin-limited ALCL,
has yet to be completely elucidated. Treatment
is largely empiric guided by presenting symptoms
and disease extent in conjunction with expectant
management emphasizing cutaneous or systemic
progression.
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